Therefore, diminution in the circulating levels of adiponectin [79, 87, 94] and in the hepatic expression of adiponectin and AdipoR2 [95] observed in obese NAFLD patients might contribute to liver PPAR-α downregulation (Figure 1B), representing an alternate reinforcing prolipogenic mechanism in addition to that related to LCPUFA n-3 depletion (Figure 1A). Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.